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Clinical trials of cell-based therapies that use pluripotent stem
cells (PSC) have already started for several neurological
diseases including spinal cord injury and age-related macular
degeneration. Regarding future PSC-based clinical trials for
other neurological diseases, these trials have been
instrumental at recognizing first, the difference between
research cell lines and clinical cell lines of a stem cell product,
second, the selection of an appropriate animal model for pre-
clinical study, third, criteria and the quality control of donor
cells, and fourth, the mode of action of the grafts.
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Introduction
Advances in research on neural stem cells (NSCs) and
pluripotent stem cells (PSCs) is expected to achieve wide
clinical application in the field of neural regenerative
medicine. Clinical trials have already started for several
diseases including age-related macular degeneration
(AMD) and spinal cord injury (SCI), and both encourag-
ing and discouraging results have been reported. In 2017,
a NSC product for clinical use (HuCNS-SC) supplied by
StemCells Inc. failed to recover motor dysfunction in
murine models of SCI [1] or show cognitive benefit in
murine models of Alzheimer’s disease [2]. The same year,
extreme results for the transplantation of retinal pigment
epithelium (RPE) cells derived from stem cells to treat
AMD patients were reported [3,4]. Finally, the launch
of a clinical trial in China for Parkinson’s disease (PD)
using an embryonic stem cells (ESC) product was
reported [5]. In this review article, I consider the transla-
tional research of stem cell-based therapies based on
these reports (Table 1).
Spinal cord injury (SCI)
Patients suffering from SCI generally show little sponta-
neous recovery and have no promising treatment options
for SCI sequela. Several early phase clinical trials of stem
cell-based therapies to treat SCI have investigated effi-
cacy and long-term safety.
As mentioned above, a clinical cell line (CCL) failed to
improve motor dysfunction in a murine model of SCI [1].
In contrast, research cell lines (RCLs) provided by the
same company demonstrated behavioral improvement in
a murine model of contusion SCI [6–8]. Based on these
results, StemCells Inc. began a clinical trial in 2014
(ClinicalTrials.gov Identifier: NCT02163876). The trial
was categorized as a single-blind, randomized, parallel
arm, phase II Proof-of-Concept study for the safety and
efficacy of HuCNS-SC transplantation in cervical SCI.
Although interim 6-month data showed improvements in
motor strength in 4/5 subjects, subsequent observation
(up to one year) could not find a trend for the improve-
ment over time, and the company terminated the study in
2016.
The lack of efficacy in the CCL study might explain the
lack of efficacy in the clinical trial and raises questions
about differences in CCLs and RCLs originating from the
same NSCs and manufactured from the same company.
CCLs are established under a current good manufactur-
ing practice (cGMP) in order to produce a reliably con-
sistent product. Therefore, it is likely that different
reagents or culture dishes were used, which could have
caused the differences between CCLs and RCLs. Alter-
natively, the discrepancy could suggest a significant dif-
ference between product batches. In this case, more strict
regulation on the manufacturing process and release
criteria of the final products will be needed. Either
way, better criteria for the evaluation of the efficacy
and safety of the CCL-derived products are necessary
before going to the clinic.
Another issue raised by this case is the limitation of rodent
models for predicting efficacy in human neurological
diseases. Results from rodent studies are not always
reflected in clinical trials, in large part because of differ-
ences in organ size and anatomy. For example, cortical
motor neurons in rodents travel in the dorsal columns of
the spinal cord and are not directly connected to cervical
motor neurons [9]. In contrast, in human and old-world
monkeys, direct connections between cortical and spinal
motor neurons are well developed, and the fibers are
located mostly in the lateral column. Therefore, one
should exercise caution when selecting an animal model
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and consider the mode of action (MOA) of the cell
products.
Regarding a cell-based therapy for SCI, several MOA
have been suggested including neuroprotection, immu-
nomodulation, axon sprouting and/or regeneration, neu-
ronal relay formation, and myelin regeneration [10]. In
the preclinical studies using HuCNS-SCs, the authors
concluded that the grafted cells differentiated into both
neurons and oligodendrocytes in the spinal cord, and
contributed to synapse formation with host neurons
and remyelination [6,7]. Remyelination by the grafted
NSCs in murine SCI models can be interpreted as a MOA
for human patients. On the other hand, murine models
may not be appropriate to predict the repair of cortico-
spinal tract in humans.
Another strategy to treat SCI is the transplantation of
human ESC-derived oligodendrocyte progenitor cells
(OPCs), which are expected to promote remyelination
[11]. A clinical trial using OPCs sponsored by Asterias
Biotherapeutics Inc. has been ongoing since 2015 (Clin-
icalTrials.gov Identifier: NCT02302157), which is an
open-label, single-arm, phase I/IIa study for severe cer-
vical SCI. Importantly, in this case, CCL-derived OPCs
(AST-OPC1) had been proved to be safe and effective in
preclinical studies using rodent SCI models [12,13]. The
update for this trial reported that 83% (15/18) and 100%
(6/6) of the patients showed motor recovery at six and
12 months, respectively [14]. In addition, there have been
no serious, unexpected, adverse events related to AST-
OPC1, the surgical procedure, or the drug used for
immunosuppression in any of the total of 30 patients.
The MOA of this strategy is more straightforward com-
pared to transplantation of NSCs, which suggests an
optimal window of the injury for treatment. It would
be expected that the clinical trial gives us an important
insight as to what kind of patients are most suitable for
this treatment.
Age-related macular degeneration (AMD)
AMD impairs visual acuity and primarily afflicts older
populations. AMD has been divided into neovascular (or
wet) and atrophic (or dry) types. Physical disruption and
functional impairment of the RPE, a monolayer sheet of
cells that supports overlying photoreceptors and underly-
ing choroidal vasculature, is the main cause of the disease,
and it is the reason why cell replacement therapy with
stem cell-derived RPE is expected.
The first clinical application of PSCs for AMD patients
used ESCs and was done by Astellas Pharma Inc. (Clin-
icalTrials.gov Identifier: NCT01344993). After one year’s
observation, the grafted ESC-derived RPE cells survived
in 13 (72%) of 18 patients. In each patient, only one eye
was treated. Visual acuity improved in 10 eyes, remained
stable in seven eyes, and continued to degenerate in one
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eye, whereas visual acuity in the untreated eyes did not
show improvements [15]. In addition, there was no evi-
dence of adverse proliferation, rejection, or serious ocular
or systemic safety issues related to the grafts. These AMD
results suggest that stem cell-derived cells could provide
a new cell source for the treatment of neurological
diseases.
The first-in-human trial using iPSCs started in 2014, and
the results of one-year-follow up were reported in
2017 [3]. In the original method used to produce iPSCs,
four transcriptional factors (c-Myc, Oct4, Sox2, Klf4) were
introduced into dermal fibroblasts by retroviral vectors
[16,17]. This method cannot be used in clinical therapies,
because the proto-oncogene c-Myc risks tumorigenesis
and the retroviral integration may cause genomic muta-
tions. Accordingly, iPSC derivation methods toward clin-
ical application have been reported including those that
replaced the c-Myc expression with L-Myc [18] and
further include LIN28 [19] and the inhibition of p53
[20,21] in the derivation protocol. Additionally, integra-
tion-free introduction of the six genes was achieved using
plasmid vectors [22]. Taking advantage, the authors of
the first-in-human trial incorporated these modifications
to derive iPSCs from the patient’s fibroblasts and induced
differentiation to produce RPE cell sheets [23]. The
follow-up study reported that the RPE cells survived
for one year in the eye, and the patient’s visual acuity
had stabilized without the injection of an anti-VEGF
drug, which the patient had received regularly before
the surgery [3]. More importantly, the patient suffered
from no serious complications and no unexpected prolif-
eration of the grafted cells during the observation period.
At the same time as this successful iPSC study, a disas-
trous clinical treatment for AMD patients was reported
[4]. In this trial, autologous adipose tissue-derived stem
cells were injected intravitreally into both eyes of three
AMD patients. Blindness occurred in one patient, and
marked visual loss in the other two.
These two extreme reports emphasize the importance of
criteria and quality control of the donor cells. Importantly,
the MOA of the grafted cells should be scientifically
established before going to the clinic. In the first trial,
the induction protocol from iPSCs to RPE cells was
rigorously confirmed, and the characteristics and function
of the induced RPE cells were confirmed by the expres-
sion of RPE markers and physiological experiments [23].
Furthermore, safety of the grafted cells was extensively
examined using immunodeficient mice [3,24]. The
RPE sheet was placed under the retina and was expected
to maintain overlying photoreceptors and underlying
choroidal vessels as the MOA. In the second trial, how-
ever, there is no evidence that the grafted cells were
differentiated into RPE cells, and the MOA of the cells
has not been reported. Despite these uncertainties, the
adipose tissue-derived stem cells were injected intravi-
treally into both eyes. Worse is that the related clinical
trial (ClinicalTrials.gov Identifier: NCT02024269) had
been withdrawn before enrollment and it was not
informed to the patients. This case exemplifies the dan-
ger of unproven stem cell therapies.
It is noteworthy that the iPSC trial had originally been
planned for two patients, but the RPE sheet transplanta-
tion for the second patient was cancelled because of three
aberrations in DNA copy number (deletions). Genomic
analysis of the iPSC-derived cells remains inconclusive
for clinical use. Although there is no evidence in the
published literature that the alterations are related to
tumorigenesis, the researchers decided to use standard
anti-VEGF treatment on the patient. Regarding genetic
changes in PSCs, there is an international survey of over
100 human PSC lines (125 ESCs and 11 iPSCs) that
concluded most lines have remained karyotypically nor-
mal, but that there is a progressive tendency to acquire
changes with prolonged culture, which commonly affect
chromosomes 1, 12, 17 and 20 [25]. Especially, a gain of
BCL2L1 on chromosome 20 provides a strong growth
advantage to PSCs. Another study also reported that a
genetic change on chromosome 20 leads to the over-
expression of BCL2L1 and escape from apoptosis [26].
More recently, TP53 mutations, which are common in
human cancers, were detected by the exome sequencing
of 140 human ESC lines, including 26 lines prepared for
potential clinical use [27]. This mutant allelic fraction
increased with passage number too, suggesting an addi-
tional selective advantage for favored expansion [28].
These two mutations are considered dangerous and
emphasize the importance of referencing cancer-related
genes listed in the COSMIC (Catalogue of Somatic
Mutations in Cancer) database when evaluating the safety
of iPSCs and their derivatives [29]. There is a chance of de
novo point mutations for iPSCs not only during cell
culture but also in the process of reprogramming, but
these latter mutations preferentially occur in lamina-
associated domains and are underrepresented in open
chromatin regions [30]. Epigenetic changes have also
been observed in PSCs and even in their somatic cells of
origin, which might affect phenotype, stability and
growth of the PSCs and their derivatives [31]. The
relationship between genetic and epigenetic changes
and tumor formation by the grafts needs to be examined
not only in preclinical studies but also in clinical trials.
Parkinson’s disease (PD)
PD is caused by the progressive loss of nigrostriatal
dopaminergic (DA) neurons, and the main symptoms
are motor dysfunctions such as tremor, rigidity and aki-
nesia. Since 1987, fetal cells from the ventral mesenceph-
alon have been grafted, and the results of clinical trials
showed that the grafted cells survived and functioned as
DA neurons over 20 years in some patients [32,33].
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However, ethical issues regarding the use of fetal tissues
and the limited amounts of accessible donor tissues have
prevented fetal cell transplantation from becoming a
standard therapy to treat PD patients. Stem cells, espe-
cially ESCs and iPSCs, are expected as alternative donor
cells.
In 2016, a phase I clinical trial using parthenogenetic stem
cells was started in Australia (ClinicalTrials.gov Identi-
fier: NCT02452723). Parthenogenetic cells are unique
because they are derived from unfertilized oocytes
through the suppression of the second meiotic division,
leading to a pluripotent diploid cell line that contains
exclusively maternal chromosomes. The trial has been
approved base on previous preclinical studies [34–37], in
which the authors induced and grafted NSCs and then
confirmed the efficacy and safety of the grafts in rat and
monkey models.
In 2017, another clinical trial using ESCs was launched in
China (ClinicalTrials.gov Identifier: NCT03119636) [5],
but the preclinical data have not yet been reported in
peer-reviewed journals.
As discussed above, the criteria of the donor cells are
critical for the efficacy and safety of any cell-based
therapy. In the trial using parthenogenetic stem cells,
the grafted NSCs were still immature and expressed
nestin and PAX6 [34]. DA neurons of the nigro-striatal
pathway are derived from the floor plate in the midbrain
[38] and never express PAX6 even in their progenitors.
Therefore, it is unlikely that the PAX6-positive NSCs
differentiate into authentic midbrain DA neurons after
transplantation. Even if some of the transplanted NSCs
become dopaminergic, they will likely be frontal DA
neurons. An alternative possible MOA for the positive
effects involves the secretion of neurotrophic factors
such as BDNF and GDNF, but this MOA is only
speculative.
The induction of midbrain DA neurons from PSCs is
performed by a combination of dual inhibition of BMP
and TGF/Activin/Nodal signals, midbrain specification
by Wnt signal activation, and ventralization by Sonic
hedgehog [39–41]. In addition, to enrich midbrain DA
progenitors and exclude immature NSCs, fluorescence-
activated cell sorting using antibodies for CORIN, a floor
plate marker [42], or ALCAM, a central nervous system
microvascular endothelium marker [43], has been devel-
oped. When grafted into the striatum of 6-OHDA-
lesioned rats [40,44] or MPTP-treated monkeys
[45,46], DA progenitors induced this way showed robust
survival and function that improved behavioral impair-
ments. In addition, human ESC-derived DA neurons
showed equal potency and efficacy to fetal midbrain
DA neurons those improved the neurological symptoms
of PD patients [47]. These results support the idea that
ESCs or iPSCs can be a cell source for a cell-based therapy
against PD.
A PET study using [18F]DOPA in monkeys showed
dopamine synthesis by the grafts [45,46], and optoge-
netic alteration of the function of the grafted cells
resulted in behavioral change of rat PD models [44].
These results suggest that the MOA of the grafted DA
neurons is reinnervation and dopamine secretion in the
striatum.
In the pursuit of better transplantation results, more
studies are being performed. A single-cell RNA sequenc-
ing revealed molecular diversity in developing mouse and
human midbrain and PSC-derived cells [48]. A combi-
nation of RNA-seq analysis of the donor cells and in vivo
studies of PD model rats following transplantation will
help identify predictive markers of the donor cells for
better outcomes [49,50]. A monkey allogeneic trans-
plantation study demonstrated that major histocompati-
bility complex-matched transplantation reduced the
immune response by the host brain and promoted the
survival of the grafted DA neurons [51].
Conclusion
2017 was year in which extremely positive and negative
findings regarding stem cell-based therapies for neural
repair were reported. These polarized findings emphasize
the importance of multiple considerations when prepar-
ing preclinical or clinical studies: first, the difference
between the RCLs and CCLs of the cell product, second,
the selection of an appropriate animal model, third, the
criteria and quality control of the donor cells, and fourth,
the MOA of the grafts. These four items are not inde-
pendent. The criteria of the donor cells define the MOA
of the grafts, and the MOA defines the inclusion and
exclusion criteria of the patients in a clinical study. In
reality, however, it might be impossible to finalize each
item before a clinical study. For this reason, the results of
clinical outcomes should be used to optimize the above
considerations (Figure 1).
For example, in the transplantation of fetal midbrain
(ventral mesencephalon) for PD patients, it became
apparent that some patients suffer from graft-induced
dyskinesia [52,53], possibly due to the contamination of
serotonergic neurons in the grafts [54]. Based on these
clinical outcomes, a new European trial using fetal
midbrain tissue, called TRANSEURO (www.
transeuro.org.uk), was initiated. In this study, the pro-
tocol design was modified to minimize the risk of graft-
induced dyskinesia [55]. The success of stem cell-based
therapies will depend on feedback from clinical out-
comes to optimize criteria for the donor cells, patient
selection, observation period and evaluation of neuro-
logical symptoms.
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